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Abstract 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is 
activated by many cytokines and growth factors and plays a key role in cell survival, prolif-
eration, and differentiation. STAT3 activation is detected virtually in all rodent models of liver 
injury and in human liver diseases. In this review, we highlight recent advances of STAT3 
signaling in liver injury, steatosis, inflammation, regeneration, fibrosis, and hepatocarcino-
genesis. The cytokines and small molecules that activate STAT3 in hepatocytes may have 
therapeutic benefits to treat acute liver injury, fatty liver disease, and alcoholic hepatitis, while 
blockage of STAT3 may have a therapeutic potential to prevent and treat liver cancer. 
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Introduction 
Alcoholic hepatitis, nonalcoholic steatohepatitis, 
and viral hepatitis are the 3 major causes of chronic 
liver diseases, leading to liver fibrosis, cirrhosis, and 
the end-stage of hepatocellular carcinoma. It is gener-
ally accepted that inflammation, characterized by an 
infiltration of inflammatory cells, plays a key role in 
promoting  the  progression  of  liver  diseases.  These 
inflammatory cells can modulate the progression of 
liver diseases by producing a wide variety  of cyto-
kines  that  activate  multiple  signaling  pathways  in 
liver cells and subsequently affect these cells. Among 
these pathways, the roles of nuclear factor-kappa B 
(NF-B) and signal transducer and activator of tran-
scription 3 (STAT3) in the pathogenesis of liver dis-
eases have been extensively investigated. It has been 
shown  that  NF-B  plays  complex  and  multicellular 
roles in hepatic inflammation, injury, fibrosis, regen-
eration, and hepatocarcinogenesis, which have been 
summarized  in  several  excellent  reviews  [1-5].  In 
2004, we summarized the role of STAT3 in liver inju-
ry,  inflammation,  and  regeneration  [6].  Since  then, 
cell-type  specific  STAT3  knockout  mice  and  gp130 
knockout  mice  have  been  made  available  and  used 
extensively to investigate the functions of STAT3 in 
many murine liver injury models. In this review, we 
highlight recent advances in STAT3 signaling in liver 
pathophysiology and discuss the potential application 
of STAT3 as a therapeutic target to treat liver diseases. 
STAT3 signaling in liver parenchymal cells 
(hepatocytes)  
The  liver,  the  largest  solid  organ  in  the  body, 
plays  a  key  role  in  metabolism,  detoxification,  and 
innate immunity [7]. Eighty percent of the liver vol-Int. J. Biol. Sci. 2011, 7 
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ume, or seventy percent of liver cells, is composed of 
hepatocytes that are responsible for the metabolic and 
detoxifying functions of the liver. The remaining cells 
are composed of Kupffer cells (liver resident macro-
phages), sinusoidal endothelial cells, stellate cells, and 
lymphocytes. It has been shown that a wide variety of 
cytokines  can  activate  STAT3  in  hepatocytes.  These 
cytokines include interleukin-6 (IL-6), the IL-6 family 
of cytokines (such as leukemia inhibitory factor, cili-
ary  neurotrophic  factor,  oncostatin  M,  cardiotro-
phin-1, and IL-11), and IL-22 [6]. IFN-/ and IFN- 
mainly induce STAT1 activation in hepatocytes, but 
also  significantly  stimulate  STAT3  activation  in 
hepatocytes  [8].  As  shown  in  Fig.  1,  the  ligation  of 
these  cytokines  to  their  receptors  induces  receptor 
dimerization, which is followed by activation of the 
receptor-associated  Janus  tyrosine  kinases  (JAKs). 
This  receptor-kinase  complex  interacts  with  and 
phosphorylates the SH2-containing cytoplasmic pro-
tein STAT3. The phosphorylated STAT3 then forms a 
dimer and translocates to the nucleus to activate the 
transcription  of  many  target  genes  that  play  im-
portant  roles  in  inducing  the  acute  phase  response, 
promoting  hepatocyte  survival  and  liver  regenera-
tion, and ameliorating steatosis. In addition, hepato-
cyte  growth  factor,  epidermal  growth  factor,  and 
hepatitis  viral  proteins  can  also  activate  STAT3  in 
hepatocytes to a lesser extent.  
 
 
Figure 1. STAT3 signaling in hepatocytes. Hepatocytes express high levels of gp130, which is a common signal chain 
for IL-6 and IL-6 family cytokines, high levels of IL-6 receptors and various corresponding receptors for IL-6 family cytokines. 
IL-6 family cytokines include leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), 
cardiotrophin-1 (CT-1), and IL-11. The ligation of these cytokines (IL-6 and IL-6 family cytokines) with their corresponding 
receptors leads to the dimerization of gp130, followed by dimerization of gp130-associated Janus kinases (JAKs) and 
phosphorylation of JAKs and gp130. This receptor-kinase complex then recruits and phosphorylates cytoplasmic protein 
STAT3. Phosphorylated STAT3 forms a dimer, translocates into the nuclei and subsequently induces transcription of many 
genes. Hepatocytes also express high levels of IL-22R1 and IL-10R2 for IL-22 signaling. IL-6, IL-6 family cytokines, and IL-22 
predominantly activate STAT3, but also induce a weak activation of other STATs and MAP kinases. Human hepatocytes 
express high levels of IFNAR1 and functional IFNAR2c (while mouse and rat hepatocytes predominantly express inhibitory 
IFNAR2a and poorly respond to IFN- stimulation). IFN-/ predominately induce STAT1 activation in primary human 
hepatocytes but also induce strong STAT3 activation. Activated STAT3 induces transcription of many genes that play 
important roles in inducing acute phase responses, promoting hepatocyte survival and liver regeneration, and ameliorating 
fatty liver.  Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
538 
STAT3 signaling in liver non-parenchymal 
cells  
Kupffer cells are liver resident macrophages that 
account for 80% to 90% of the total population of fixed 
tissue macrophages in the body. Kupffer cells are the 
major source not only of proinflammatory cytokines 
such as IL-6, but also of anti-inflammatory cytokines 
such as IL-10. In addition, Kupffer cells can also re-
spond to IL-6 and IL-10. Notably, both IL-6 and IL-10 
induce  STAT3  activation  in  macrophages,  but  exert 
opposing functions. While IL-10 induces STAT3 acti-
vation  and  subsequently  inhibits  LPS-induced  in-
flammatory  responses  in  macrophages  and  Kupffer 
cells [9-11], IL-6 also activates STAT3 but potentiates 
proinflammatory  responses  in  peritoneal  macro-
phages [12]. Although the effect of IL-6 on Kupffer 
cells has not been investigated, it is plausible to spec-
ulate  that  IL-6  may  also  promote  proinflammatory 
responses  in  Kupffer  cells.  The  reason  why  STAT3 
activation by IL-10 or IL-6 inhibits or promotes, re-
spectively,  the  macrophage  inflammatory  response 
remains unclear. It has been shown that both IL-6 and 
IL-10  activate  STAT3  and  subsequently  upregulate 
expression  of  suppressor  of  cytokine  signaling  3 
(SOCS3)  in  macrophages  [12].  SOCS3  then,  in  turn, 
inhibits IL-6 signaling via binding to gp130, resulting 
in IL-6 induction of transient STAT3 activation, while 
SOCS3  does  not  block  IL-10  activation  of  STAT3; 
therefore, IL-10 induces prolonged STAT3 activation 
(Fig. 2) [12]. It is believed that IL-6 induction of tran-
sient  STAT3  activation  is  responsible  for  its 
pro-inflammatory response, while IL-10 induces pro-
longed  STAT3  activation  and  subsequently  inhibits 
inflammatory responses in macrophages [12]. In ad-
dition,  the  effects  of  other  IL-6 family  cytokines  on 
STAT3 activation and pro-inflammatory responses in 
Kupffer cells remain largely unknown.  
 
 
Figure 2. STAT3 signaling in Kupffer cells. Kupffer cells express high levels of IL-10R1 and IL-10R2. The ligation of 
IL-10 with IL-10R1 and IL-10R2 leads to prolonged activation of STAT3, thereby inhibiting inflammatory responses. In 
contrast, the ligation of IL-6 with IL-6R and gp130, which are expressed at high levels on Kupffer cells, leads to transient 
activation of STAT3, followed by the induction of inflammatory responses. STAT3 activation induces expression of SOCS3, 
which in turns inhibits IL-6 activation of STAT3, but does not inhibit IL-10 signaling.  Int. J. Biol. Sci. 2011, 7 
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Figure 3. STAT3 signaling in hepatic stellate cells. Hepatic stellate cells express high levels of the long form of the 
leptin receptor (OBRL). The ligation of leptin with OBRL induces activation of STAT3, leading to stellate cell activation, 
proliferation, and survival. IL-6 can also stimulate stellate cell survival, proliferation, and activation via binding of IL-6R and 
gp130 on stellate cells. 
 
 
Hepatic stellate cells are located in the space of 
Disse (a small area between the endothelial cells and 
hepatocytes) and store 75% of the body’s supply of 
vitamin A. Activation of hepatic stellate cells plays a 
key role in the pathogenesis of liver fibrosis via pro-
ducing extracellular matrix proteins [13,14]. IL-6 and 
leptin have been shown to activate STAT3 in hepatic 
stellate cells and promote their survival and prolifer-
ation,  thereby  contributing  to  liver  fibrogenesis 
[15,16]. However, the exact role of STAT3 in hepatic 
stellate cells remains to be determined.  
Liver  sinusoidal  endothelial  cells  lack  a  base-
ment membrane and form a fenestrated monolayer, 
separating hepatocytes from the passing blood. It has 
been shown that IL-6 treatment activates STAT3 and 
protects  against  cell  death  in  liver  sinusoidal  endo-
thelial cells [17,18]. 
STAT3 in fatty liver and glucose metabolism 
Fatty liver (accumulation of fat in hepatocytes) is 
mainly caused by alcohol consumption and obesity, 
but can also be caused by metabolic diseases, nutri-
tional  factors,  drugs,  toxins,  genotype  3  hepatitis  C 
infection,  and  alpha  1-antitrypsin  deficiency.  The 
presence of a fatty liver was considered to be a benign 
feature in the past, but is now known to be prone to 
steatohepatitis, fibrosis, and hepatocellular carcinoma 
[19-21]. Excess fat accumulation in hepatocytes may 
lead to hepatocellular injury via direct cellular cyto-
toxicity mediated by FFAs, oxidative stress, lipid pe-
roxidation,  mitochondrial  impairment,  and  cyto-
kine-induced hepatoxicity [19-23]. For example, both 
IL-1 and TNF- have been shown to promote hepa-
tocellular damage and the development of fatty liver 
[24-26].  In  contrast,  several  cytokines  that  activate 
STAT3 in hepatocytes are known to ameliorate fatty 
liver. IL-6 deficient-mice are more susceptible to al-
cohol-  and  high-fat  diet-induced  fatty  liver  [27,28], 
while treatment with IL-6 ameliorates fatty liver [29]. 
Recent studies also showed that treatment with IL-22 Int. J. Biol. Sci. 2011, 7 
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induces STAT3 activation in the liver and alleviates 
steatosis induced by alcohol or high-fat diet feeding 
[30,31]. The protective effect of IL-22 on alcoholic fatty 
liver  is  diminished  in  hepatocyte-specific  STAT3 
knockout mice [30], suggesting that IL-22 ameliorates 
steatosis through activation of STAT3 in hepatocytes. 
Furthermore,  disruption  of  gp130  (upstream  of 
STAT3)  or  STAT3  in  hepatocytes  exacerbates  fatty 
liver  induced  by  a  choline-deficient,  ethio-
nine-supplemented diet [32], alcohol-containing diet 
[33], or high-fat diet [34], whereas overexpression of 
constitutively  activated  STAT3  ameliorates  high-fat 
diet-induced fatty liver [34]. The anti-steatogenic ef-
fect of hepatocyte STAT3 is mediated, at least in part, 
via inhibition of SREBP-1, a master transcription fac-
tor that controls lipid synthesis, and subsequent sup-
pression of hepatic lipogenesis [33,34]. However, the 
mechanism  by  which  STAT3  represses  SREBP-1  re-
mains to be determined.  
In  addition  to  controlling  lipid  metabolism, 
STAT3  signaling  also  plays  an  important  role  in 
maintaining  normal  glucose  homeostasis  via  down-
regulation of hepatic gluconeogenic genes, including 
glucose-6-phosphatase  (G6Pase)  and  phosphoe-
nolpyruvate  carboxykinase  (PEPCK),  in  hepatocytes 
[34,35].  STAT3  activation  inhibits  expression  of 
G6Pase and PEPCK in both cultured hepatocytes and 
mouse liver; such inhibition is mediated via STAT3 
binding to the promoters of the G6Pase and PEPCK 
genes [35].  
STAT3 in liver injury and inflammation 
STAT3 in hepatocytes:  It  has  been  reported  that 
treatment  with  IL-6,  IL-6  family  cytokines,  or  IL-22 
protects against liver injury in many rodent models 
[6,17,29,36-39],  while  blockage  of  IL-22  with  a  neu-
tralizing antibody exacerbates liver injury induced by 
Con  A  injection  [37,40]  or  by  viral  infection  [41]. 
Transgenic mice with overexpression of IL-22 in the 
liver  are  completely  resistant  to  T  cell  hepati-
tis-induced  hepatocellular  damage  [42].  Moreover, 
disruption of the IL-6/gp130, OSM, or IL-22 genes, or 
hepatocyte STAT3, increases the susceptibility of mice 
to  liver  injury  in  most  animal  models  tested  so  far 
[6,43-53].  All  of  these  findings  clearly  demonstrate 
that  STAT3  plays  a  key  role  in  protecting  against 
hepatocellular  damage.  In  contrast  to  the 
well-documented  hepatoprotection,  hepatocyte 
STAT3 has a more complex role in liver inflammation. 
Compared  to  wild-type  mice,  hepatocyte-specific 
STAT3 knockout mice have reduced liver inflamma-
tion in models of liver injury induced by acute carbon 
tetrachloride injection [50] or alcohol feeding [33] but 
elevated liver inflammation in Con A-induced T cell 
hepatitis  (Lafdil  and  Gao,  unpublished  data)  or  in 
LPS-induced  liver  injury  [54],  suggesting  that 
hepatocyte STAT3 acts as either a pro-inflammatory 
or an anti-inflammatory signal according to the mod-
els. The pro-inflammatory effect of hepatocyte STAT3 
is  likely  mediated  via  its  induction  of  acute  phase 
proteins and chemokines in the liver [33,50]. In con-
trast, activation of hepatocyte STAT3 protects against 
hepatocellular  damage  and  subsequently  reduces 
liver  necrosis-associated  inflammation.  Hepatocyte 
STAT3  also  inhibits  IFN--activated  STAT1,  a  key 
proinflammatory  signal  in  the  liver  [55],  thereby 
playing  an  important  role  in  attenuating  inflamma-
tory responses. In both Con A-induced T cell hepatitis 
and LPS-induced liver injury models, IFN- is mark-
edly  elevated,  and  STAT1  is  highly  activated  in 
hepatocytes  [54,56],  whereas  such  activation  is  not 
observed  in  CCl4-  or  alcohol-induced  liver  injury 
models.  Therefore,  activation  of  STAT3  inhibits 
STAT1  activation  in  the  liver  and  subsequently  re-
presses  liver  inflammation  in  both  Con  A-  and 
LPS-induced  liver  injury  models  [54,56].  However, 
such anti-inflammatory effects of STAT3 may not oc-
cur in CCl4- or alcohol-induced liver injury models, as 
the IFN-/STAT1 signaling pathway is not upregu-
lated in these models.  
STAT3  in  macrophages/Kupffer  cells:  The  an-
ti-inflammatory effect of STAT3 in myeloid cells, in-
cluding  macrophages/Kupffer  cells,  has  been 
well-documented in various models of organ injury, 
including  liver  injury  [33,50,57-59],  and  in  cultured 
Kupffer cells [33]. However, the role of STAT3 in my-
eloid cells in hepatocellular damage remains obscure. 
Interestingly, a specific deletion of STAT3 in myeloid 
cells  enhances  the  susceptibility  of  mice  to  Con 
A-induced  T  cell  hepatitis  [58]  and alcohol-induced 
liver  injury  [33],  but  reduces  CCl4-induced  hepato-
cellular  damage  [50].  This  opposing  effect  could  be 
attributable to the deletion of STAT3 in myeloid cells, 
preferentially  augmenting  IFN-  production  that 
subsequently enhances liver injury in Con A-induced 
T  cell  hepatitis  [58],  while  preferentially  enhancing 
IL-6  production  that  consequently  protects  against 
hepatocellular  damage  in  CCl4-induced  liver  injury 
[50].  Collectively,  STAT3  in  myeloid  cells  not  only 
inhibits  expression  of  pro-inflammatory  cytokines, 
such as TNF- and IFN-, that induce liver damage 
and  inflammation,  but  also  represses  production  of 
hepatoprotective  cytokines,  such  as  IL-6  and  IL-22, 
that ameliorate liver injury [58]. Thus, the outcome of 
myeloid  STAT3  on  hepatocellular  damage  is  likely 
determined by the balance between detrimental and 
hepatoprotective  cytokines  produced  during  liver 
injury.  Int. J. Biol. Sci. 2011, 7 
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STAT3 in endothelial cells: Previous studies sug-
gest that STAT3 signaling in endothelial cells plays an 
important  role  in  inhibiting  inflammation  and  pro-
tecting against LPS-induced inflammation [60-62], but 
the role of endothelial cell STAT3 in liver injury and 
inflammation  has  not  been  extensively  studied.  We 
have previously reported that endothelial cell-specific 
STAT3  knockout  mice  were  more  susceptible  to  al-
cohol-induced  liver  injury  and  inflammation  [63], 
suggesting  that  endothelial  cell  STAT3  plays  im-
portant  dual  functions  of  attenuating  hepatic  in-
flammation and sinusoidal endothelial cell apoptosis 
during  alcoholic  liver  injury.  However,  the  role  of 
STAT3  in  liver  injury  and  inflammation  in  other 
models remains to be determined.  
STAT3 and liver regeneration 
The  liver  is  the  only  solid  organ  in  mammals 
with  amazing  regenerative  capabilities  after  loss  of 
tissue or injury [64-66]. Emerging evidence suggests 
that liver regeneration is controlled by a wide variety 
of  cytokines,  growth  factors,  hormones,  and  their 
downstream  signaling  pathways  [64-66].  Among 
them, the roles of IL-6 and its downstream signaling 
molecule STAT3 in liver regeneration have been ex-
tensively  investigated  [64-66].  In  addition,  several 
other IL-6 family cytokines and IL-22, which activate 
STAT3 in hepatocytes, are also reported to promote 
liver  regeneration  [47,67,68],  while  the  an-
ti-inflammatory  cytokine  IL-10,  which  activates 
STAT3  in  immune  cells,  has  been  shown  to  inhibit 
liver regeneration via suppression of the proinflam-
matory response during liver regeneration [69].  
Two-third partial hepatectomy (PHx) is a widely 
used  model  to  study  liver  regeneration.  It  is 
well-established  that  after  PHx,  the  ability  of  the 
remnant liver to detoxify endotoxin (LPS) decreases, 
leading to elevation of hepatic LPS levels [70,71]. LPS 
stimulates Kupffer cells to produce inflammatory cy-
tokines, including TNF- and IL-6, that subsequently 
initiate liver regeneration. This priming phase usually 
takes place shortly after PHx with a transient increase 
in low inflammation. This notion was supported by 
studies  using  several  strains  of  knockout  mice.  For 
example, genetic deletion of the type I TNF receptor 
(TNFR-1) resulted in an increase of the mortality rate 
in mice after PHx, and was accompanied by reduced 
hepatocyte proliferation [72]. Similarly, IL-6 deficient 
mice, reported initially by Cressman et al. [73], had 
increased  mortality,  blunted  hepatocyte  DNA  syn-
thesis, and repressed AP-1, Myc, and cyclin D with an 
absence  of  STAT3  activation  after  PHx.  Treatment 
with  a  single  preoperative  dose  of  IL-6  restored 
STAT3  binding  and  hepatocyte  proliferation  and 
prevented  liver  damage  in  IL-6-deficient  mice  [73]. 
This study strongly posited an important role for IL-6 
in  hepatocyte  proliferation  via  activation  STAT3. 
However,  several  follow-up  studies  using  IL-6 
knockout mice generated conflicting data on the role 
of IL-6 on liver regeneration. Sakamoto et al. [74] re-
ported that the peak of hepatocyte proliferation was 
only reduced by 20-30% in IL-6-deficient mice com-
pared  with  wild-type  mice  after  PHx,  and  similar 
mortality  was observed in both groups,  while Blin-
denbacher et al. [75] reported that IL-6-deficient mice 
had higher mortality after PHx but that the surviving 
IL-6-deficient mice had similar hepatocyte prolifera-
tion  compared  to  wild-type  mice.  In  addition,  two 
later  studies  demonstrated  that  IL-6  knockout  mice 
and wild-type mice had similar hepatocyte prolifera-
tion after PHx [76,77]. Systemic delivery of high levels 
of IL-6 using CHO cell tumors in nude mice resulted 
in  a  dramatic  induction  of  hepatocyte  proliferation 
and hepatomegaly via activation of the MAPK/ERK 
and  STAT3  signaling  pathways  [78].  However,  hy-
perstimulation  with  IL-6  in  transgenic  mice  with 
overexpression  of  the  human  soluble  IL-6  recep-
tor/gp80 in hepatocytes before PHx resulted in de-
layed and inhibited cell cycle progression after PHx in 
mice [79]. The reasons for these controversial reports 
on the role of IL-6 in liver regeneration are not clear 
and may be due to using different surgery techniques, 
strains of mice, or research environments. Despite of 
these  controversial  reports,  most  investigators  still 
accepted the notion that IL-6 plays an important role 
in liver regeneration [80-82]. Furthermore, several IL-6 
family cytokines, such as oncostatin M [47] and car-
diotrophin-1 [36], have also been shown to promote 
liver regeneration in various models. IL-22 was also 
shown to play a role in promoting liver regeneration 
after PHx [83].  
In contrast to the cytokines that activate STAT3 
in  hepatocytes  and  promote  liver  regeneration  dis-
cussed above, the anti-inflammatory cytokine IL-10, 
which activates STAT3 in immune cells (e.g., macro-
phages), but not in hepatocytes, may negatively reg-
ulate  liver  regeneration.  Expression  of  IL-10  in  the 
liver is upregulated after PHx [69]. Disruption of IL-10 
enhances  liver  inflammation  and  regenerative  re-
sponses with increased STAT3 activation in the liver 
[69]. An additional deletion of hepatocyte STAT3 re-
duced liver regeneration in IL-10-deficient mice [69], 
suggesting that enhanced liver regeneration in IL-10 
knockout mice is due to elevated IL-6/STAT3 activa-
tion in the liver.  
Rapid  activation  of  STAT3  has  been 
well-documented during liver regeneration after PHx 
or  liver  injury  [59,84-86].  After  PHx,  activation  of Int. J. Biol. Sci. 2011, 7 
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STAT3 was first detected in Kupffer cells and in si-
nusoidal  endothelial  cells  and  later  detected  in 
hepatocytes  localized  in  the  periportal  zones  of  he-
patic lobules in rats [86]. As global disruption of the 
STAT3  gene  leads  to  early  embryonic  death,  tis-
sue-specific STAT3 knockout mice were generated to 
investigate  the  biological  impact  of  STAT3  in  liver 
regeneration. Studies from our lab and other groups 
showed that deletion of STAT3 in hepatocytes only 
moderately  reduced  liver  regeneration  without  in-
duction of hepatocyte apoptosis after PHx [59,85,87]. 
Several STAT3 targeted genes have been  identified; 
these include cyclin D and c-myc, which induce the 
cell-cycle transition from the G1 to the S phase, and 
bcl-2, bcl-xl, mcl-1, and c-Flip, which protect against 
hepatocyte apoptosis [85]. STAT3 in immune cells was 
also markedly activated by PHx, and conditional de-
letion  of  STAT3  in  myeloid  linage  cells  resulted  in 
enhanced inflammatory response and increased liver 
regeneration  [59]. Combined conditional ablation of 
STAT3 in both hepatocytes and myeloid cells resulted 
in a dramatic reduction in survival with elevated ac-
tivation  of  STAT1  and  hepatocyte  apoptosis  after 
PHx,  as  compared  to  wild-type  or  single  knockout 
animals [59]. These findings suggest that the interplay 
of STAT3 in myeloid cells and hepatocytes plays an 
important role in ensuring normal liver regeneration 
via  tempering  systemic  and  hepatic  innate  inflam-
matory responses [59]. Activation of STAT3 also in-
duces expression of SOCS3, which in turn terminates 
STAT3  signaling  and  negatively  regulates  liver  re-
generation [88]. Interestingly, recent studies from Dr. 
Ozaki’s group suggest that PDK1/Akt signaling also 
contributes  to  liver  regeneration  by  regulating  cell 
size [89,90].  
In  summary,  the  role  of  hepatocyte  STAT3  in 
liver regeneration has been extensively investigated, 
and it is generally accepted that activation of STAT3 
in hepatocytes promotes hepatocyte proliferation af-
ter PHx or loss of tissue, while myeloid cell STAT3 
activation  seems  to  suppress  liver  regeneration  via 
inhibiting  inflammatory  responses.  In  contrast,  the 
roles of STAT3 in other immune cells and sinusoidal 
endothelial cells in liver regeneration have not been 
explored  and  deserved  further  studies.  In  addition, 
the  interplay  of  STAT3  from  different  cell  types  in 
liver regeneration likely plays a critical role in ensur-
ing normal liver regeneration, which also needs fur-
ther investigation.  
STAT3 in liver fibrosis 
Liver  fibrosis,  or  cirrhosis,  is  a  common 
end-stage  condition  of  many  chronic  liver  diseases 
after  incomplete  recovery  from  hepatocyte  damage. 
During fibrosis progression, inflammation and liver 
injury  trigger  complex  cellular  events  that  result  in 
collagen deposition and disruption of the normal liver 
architecture. Generally, activated hepatic stellate cells 
are considered the most important cell type for the 
production of collagens [14,91]. More recent research 
suggests  that  myofibroblasts,  bone  marrow-derived 
progenitor cells, and hepatocytes may also contribute 
to fibrogenesis via production of collagens [14,91,92], 
and immune cells may regulate fibrogenesis via pro-
duction of a wide variety of cytokines; among them, 
TGF- has been shown to promote liver fibrosis via 
stimulating hepatic stellate cell activation, while IFN- 
is known to inhibit liver fibrosis via inducing hepatic 
stellate  cell  apoptosis  and  cell  cycle  arrest  [14,91]. 
Although the hepatoprotection ability of IL-6, one of 
the most important cytokines to activate STAT3 in the 
liver, has been well-documented, the data on the role 
of IL-6 in liver fibrogenesis from animal models re-
main controversial.  
Initial  experiments  showed  that  IL-6  knockout 
mice  were  more  susceptible  to  CCl4-induced  liver 
injury and fibrosis [93], while other reports demon-
strated  reduced  liver  fibrosis  in  IL-6-deficient  mice 
after CCl4 treatment [94,95]. The reasons for the dis-
crepancy between these studies are not clear. In addi-
tion, deletion of gp130 (the common signal transducer 
of IL-6 family cytokines) in hepatocytes had no effect 
on  liver  fibrosis,  while  deletion  of  gp130  in  nonpa-
renchymal liver cells aggravated fibrosis progression 
[45]. In vitro culture experiments showed that Kupffer 
cell-derived  IL-6  promotes  hepatic  stellate  cell  sur-
vival and proliferation [15]. Clinical studies showed 
that  hepatic  IL-6  expression  was  upregulated  and 
correlated positively with the degree of liver fibrosis 
in opisthorchiasis periductal fibrosis and in nonalcoholic 
steatohepatitis  [96,97].  Furthermore,  genetic  poly-
morphisms of IL-6 were reported to modulate fibrosis 
progression in patients with mild chronic hepatitis C 
(HCV)  [98].  Because  IL-6  receptors  are  expressed 
ubiquitously on all types of liver cells, it is plausible to 
speculate  that  IL-6  may  positively  and  negatively 
regulate liver fibrosis via targeting different types of 
liver cells. For example, IL-6 protects against hepato-
cellular damage, thereby reducing liver fibrosis, while 
IL-6  may  also  directly  promote  hepatic  stellate  cell 
survival  and  proliferation,  followed  by  enhancing 
liver fibrosis. The final effect of IL-6 on liver fibrosis is 
likely  determined  by  the  balance  between  these  in-
hibitory and stimulatory effects and is dependent on 
the stage and etiology of liver fibrosis.  
The  initial  clue  for  the  role  of  the  IL-6  down-
stream signaling molecule STAT3 in liver fibrogenesis 
is  emerging  from  the  clinical  observations  of  Dr. Int. J. Biol. Sci. 2011, 7 
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Starkel’s  group  [99].  This  study  documented  that 
STAT3 expression and phosphorylation were not al-
tered in HCV-fibrosis patients and alcoholic cirrhosis, 
while STAT3-DNA binding was markedly suppressed 
in all alcoholic and most HCV fibrotic patients when 
compared  with  to  normal  healthy  livers.  This  im-
paired STAT3-DNA binding might contribute to dis-
turbed liver regeneration and repair in these patients. 
Further  studies  from  the  same  group  later  showed 
that  fibrosis  progression  in  HCV-infected  patients 
correlated  positively  with  a  continuous  decline  in 
STAT3-DNA binding activity. This decreased STAT3 
activity also correlated with reduced hepatocyte pro-
liferation and a positive anti-apoptotic balance in in-
filtrating  inflammatory cells that are known media-
tors  of  cell  damage  in  HCV  [100].  Taken  together, 
these clinical studies indicate that STAT3 may ame-
liorate  HCV  and  alcohol-related  liver  fibrosis  via 
protecting against hepatocellular damage.  
Recent studies from animal models suggest the 
STAT3 in hepatocytes plays a protective role in pre-
venting  liver  fibrosis,  mainly  because  of  STAT3’s 
hepatoprotective  and  proliferative  functions 
[50,53,101]. The hepatoprotective function of STAT3 
in the liver has been well-documented in many mu-
rine models of liver injury as discussed in above sec-
tions. Thus, it is probable that activation of STAT3 in 
hepatocytes may suppress liver fibrosis via prevent-
ing hepatocyte damage. This speculation is, indeed, 
supported by the studies from several animal models. 
In  the  models  of  Sclerosing  Cholangitis,  which  use 
mice  lacking  the  multidrug  resistance  gene  2 
(mdr2-/-), conditionally inactivated STAT3 in hepato-
cytes and cholangiocytes leads to strongly aggravated 
hepatocellular damage and fibrosis [53]. The hepato-
protective role of STAT3 is likely due to activation of 
EGFR and IGF-1 signaling pathways in hepatocytes, 
thereby preventing bile acid–induced liver injury and 
fibrosis  [53].  Similarly,  another  study  showed  that 
lack of gp130/STAT3-mediated signaling in hepato-
cytes  resulted  in  enhanced  chronic  cholestatic  liver 
injury  and  fibrosis  progression  induced  by 
3,5-diethoxycarbonyl-1,4-dihydrocollidine  (DDC) 
[101].  Deletion  of  the  gp130/STAT3  pathway  in 
hepatocytes leads to more severe liver injury and an 
enhanced  inflammatory  response  with  increased 
TNF- expression and subsequent cytotoxicity. This 
greater chronic liver injury leads to enhanced hepatic 
stellate cell activation and a profibrogenic response. In 
contrast, Ogata et al. [102] reported that deletion of 
SOCS3 (a protein with a strong inhibitory effect on 
STAT3 signaling) in the liver, via injection of adeno-
virus dominant STAT3 or in the SOCS3flox/flox mice via 
injection of adenovirus Cre, resulted in hyperactiva-
tion of STAT3 in the liver and enhanced hepatic fi-
brosis through the production of TGF-β1. Although 
adenovirus  mainly  infects  hepatocytes,  it  may  also 
infect other liver cells including hepatic stellate cells 
and  Kupffer  cells.  Thus,  it  is  not  clear  whether  en-
hanced liver fibrosis in the models reported by Ogata 
et al. [102] is due to deletion of SOCS3 in hepatocytes 
or in other nonparenchymal cells.  
Until now, the functions of STAT3 in nonparen-
chymal liver cells and inflammatory cells during liver 
fibrogenesis  are  largely  unknown.  Several  studies 
provide  indirect  evidence  of  profibrogenic  and  sur-
vival roles of STAT3 in hepatic stellate cells. Leptin is 
an  important  pro-fibrogenic  cytokine  that  activates 
STAT3 in hepatic stellate cells [103,104]. Inhibition of 
JAK/STAT3  activation  by  a  specific  JAK2  inhibitor 
AG490 prevents hepatic stellate cell early activation 
[105].  In  addition,  STAT3  is  involved  in  lep-
tin-mediated  production  of  TIMP-1,  an  important 
survival  factor  for  hepatic  stellate  cells  [106].  Other 
mechanisms  leading  to  fibrogenesis  via  STAT3  sig-
naling  pathway  activation  in  hepatic  stellate  cells, 
such as phagocytosis of apoptotic bodies, have been 
shown to promote their survival [107]. Kupffer cells 
also  play  an  important  role  in  the  pathogenesis  of 
leptin-induced  liver  fibrosis  [108].  Treatment  with 
leptin potentiated activation of STAT3, Akt, and ex-
tracellular signal-related kinase 1/2 phosphorylation 
in Kupffer cells and increased AP-1 and nuclear fac-
tor-kappaB DNA binding. Blockage of STAT3 activa-
tion by a STAT3 inhibitor attenuated TGFβ1 produc-
tion by Kupffer cells [108]. These observations indi-
cate  that  leptin  may  promote  liver  fibrogenesis  via 
activation  of  STAT3  and  subsequent  production  of 
TGF-  in  Kupffer  cells.  Additional  studies  are  re-
quired to clarify the roles of STAT3 in hepatic stellate 
cells, Kupffer cells, sinusoidal cells, and inflammatory 
cells in the pathogenesis of liver fibrosis. 
STAT3 and liver cancer 
Aberrantly hyperactivated IL-6-STAT3 signaling 
in cancer cells and the tumor microenvironment has 
been detected in a wide variety of human cancers and 
is considered to be an important factor for cancer ini-
tiation, development, and progression [109-112]. The 
interplay  of  STAT3  in  cancer  cells  and  other  cells 
around cancer cells likely plays an important role in 
modulating tumor growth via several steps. First, it is 
well known that IL-6-STAT3 signaling is crucial for 
tumor cell proliferation and survival via induction a 
variety  of  protooncogenes  [113-115].  In  contrast  to 
normal cells, in which STAT3 activation is rapid and 
transient,  cancer  cells  routinely  harbor  persistently 
activated STAT3 proteins that promote a permanent Int. J. Biol. Sci. 2011, 7 
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alteration of some genes that control cellular process-
es. Constitutively activated STAT3 promotes tumor-
igenesis  through  the  upregulation  of  cell  survival 
proteins (Bcl-xl and Bcl-2), cell cycle regulators (c-Myc 
and  cyclin  D)  [112,114,116,117],  anti-oxidant  genes 
(Mn-SOD,  ferritin,  and  catalse),  and  tissue  repair 
genes  (RegIII,  RegIII,  and  Tff3)  [114,118,119].  Se-
cond,  persistent  activation  of  STAT3  also  increases 
angiogenesis and metastasis via upregulation of vas-
cular endothelial growth factor (VEGF), hypoxia in-
ducible  factor  1  alpha  (HIF1)  and  basic  fibroblast 
growth factor (bFGF), all of which are important me-
diators  of  angiogenesis  during  tumor  formation 
[120-122]. Third, the persistent activation of STAT3 in 
immune/inflammatory cells is also very important in 
the  control  of  tumor  promotion  and  progression 
through  tumor-promoting  inflammation  and  sup-
pressing anti-tumor immunity [123]. Recently, a key 
novel  molecule,  sphingosine-1-phosphate  receptor-1 
(S1PR1), that is induced by STAT3 has been uncov-
ered to play an important role in inducing persistent 
STAT3 activation  in  tumor  cells  and  the  tumor  mi-
croenvironment  [124].  In  summary,  STAT3  can 
broadly  and  profoundly  affect  tumor  growth  via 
stimulation of tumor cell survival and proliferation, 
induction  of  tumor  angiogenesis,  and  suppressing 
anti-tumor  immunity.  Thus,  constitutively  activated 
STAT3  both  in  tumor  cells  and  tumor  stromal  im-
mune cells is an attractive target for cancer treatment 
[125].  
Hepatocellular  carcinoma  (HCC)  is  the  most 
common  primary  malignancy  of  the  liver  in  adults 
and the third leading cause of cancer deaths world-
wide, with few effective therapeutic options for this 
advanced  disease  [126-128].  Most  HCC  appears  in 
cirrhotic livers after years of chronic liver inflamma-
tion  caused  by  viral  hepatitis  and  alcoholic  and 
non-alcoholic  steatohepatitis  [127,129].  Several  cyto-
kines (such as IL-6, IL-6 family cytokines, IL-22, etc) 
that activate STAT3 in hepatocytes have been shown 
to  promote  HCC  growth  in  vitro  and  in  vivo 
[37,42,130]. Clinical studies reported that serum IL-6 
concentrations were elevated in patients with chronic 
liver inflammation, including alcoholic hepatitis, viral 
hepatitis,  and  nonalcoholic  steatohepatitis,  and  in 
patients  with  HCC  [131].  Notably,  men  are  about 
three to five times more likely to develop HCC than 
women  [132].  A  similar  gender  disparity  was  also 
seen in a murine model of HCC induced by diethyl-
nitrosamine (DEN). It is believed that higher serum 
levels of IL-6 in male mice contributed to the higher 
susceptibility to DEN-induced liver cancer compared 
to female mice [130]. In addition to IL-6, IL-22 and 
leptin, which also activate STAT3 in liver cancer cells, 
have  also  been  implicated  in  liver  tumorigenesis. 
IL-22, a recently identified IL-10 family cytokine, also 
activates STAT3 in hepatocytes and has been shown 
to  promote  HCC  in  vitro  and  in  vivo  [37].  In  vitro 
treatment with IL-22 or overexpression of IL-22 pro-
motes cell growth and survival of human hepatoma 
HepG2 cells. Stable overexpression of IL-22 in HepG2 
cells constitutively activates STAT3 and upregulates 
expression of a variety of anti-apoptotic (e.g., Bcl-2, 
Bcl-xl, and Mcl-1) and mitogenic (e.g., c-myc, cyclin 
D1, Rb2, and CDK4) proteins. Overexpression of IL-22 
in HepG2 and Hep3B cells also promotes tumor for-
mation  of  these  cells  in  nude  mice  [37].  Transgenic 
mice  with  overexpression  of  IL-22  in  the  liver  are 
more susceptible to DEN-induced liver tumorigenesis 
[42]. Leptin is an adipose-derived hormone that plays 
an  important  role  in  food  intake  and  energy  ex-
penditure. Recent studies showed that leptin also ac-
tivates STAT3 in liver cancer cells and promotes liver 
cancer cell survival and proliferation [133-135].  
STAT3 is the major downstream signaling mol-
ecule of IL-6, IL-22, and leptin in hepatocytes. Several 
lines  of  evidence  suggest  that  STAT3  plays  an  im-
portant role in the development of liver cancer. First, 
constitutively activated STAT3 is detected in human 
hepatoma cells and human liver tumor tissues [136]. 
In HCC tissues, strong STAT3 immunostaining was 
observed  in  the  cytoplasm,  and  pY705STAT3  im-
munostaining was observed in the nucleus [136]. In 
addition, blockage of STAT3 using chemical inhibitors 
or siRNA induced liver cancer cell apoptosis and cell 
cycle  arrest  in  vitro  and  inhibited  growth  of  trans-
planted  liver  cancer  cells  in  vivo  [136-138].  Second, 
altered p-STAT3 expression was positively correlated 
with  the  histological  grading  and  intra-tumor  mi-
crovessel  density  in  HCC  [139].  Third,  deletion  or 
methylation silencing of hepatic SOCS3, an inhibitor 
for STAT3, resulted in enhanced STAT3 activation in 
the liver and accelerated DEN-induced liver tumor-
igenesis [88,140], while overexpression of SOCS3 in-
hibited HCC cell growth [141]. Finally, the conclusive 
evidence for an important role of STAT3 in liver can-
cer development is from the fact that conditional de-
letion  of  STAT3  in  hepatocytes  prevented 
DEN-induced liver cancer development in mice [142]. 
Notably, recent studies suggest that STAT3 activation 
is  also  implicated  in  HCV-  and  obesity-mediated 
hepatocarcinogenesis  [143,144].  Another  important 
line of evidence for the role of STAT3 in liver cancer 
development is that constitutively activated STAT3 is 
detected  in  cancer  stem  cells  from  HCC  and  likely 
contributes to liver cancer stem cell proliferation and 
survival [145]. Collectively, activation of STAT3 plays 
an important role in liver tumorigenesis. Blockage of Int. J. Biol. Sci. 2011, 7 
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STAT3 may have a therapeutic potential in preventing 
and treating liver cancer.  
STAT3 as a therapeutic target to treat liver 
disease 
Because  the  hepatoprotection  and  an-
ti-steatogenic  effects  of  hepatocyte  STAT3  are 
well-established,  the  cytokines  and  small  molecules 
that activate STAT3 in hepatocytes may have a ther-
apeutic potential to treat acute liver injury and fatty 
liver  diseases.  IL-6  has  been  shown  to  effectively 
ameliorate liver injury and fatty liver diseases in an-
imal models [17,29,38]. However, the clinical applica-
tion of IL-6 in patients has been halted owing to many 
adverse effects of IL-6 that are likely caused by ubiq-
uitous expression of the IL-6 receptor, IL-6 receptor 
signal  chain  gp130,  and  the  existence  of  circulating 
soluble IL-6 receptor. In addition, patients with liver 
diseases are always associated with highly elevated 
levels of IL-6 [96,97,146,147], resulting in resistance to 
IL-6  treatment.  Interestingly,  we  have  recently 
demonstrated  that  ex  vivo  treatment  of  fatty  donor 
liver with IL-6 prevents fatty liver transplant failure 
via improving microcirculation and reducing liver cell 
apoptosis [17]. Application of IL-6 ex vivo could be a 
magic potion to prevent fatty liver transplant failure 
in humans [148].  
Since  IL-22  receptor  expression  is  restricted  to 
epithelial  cells,  including  hepatocytes,  in  vivo  IL-22 
treatment will likely have few side effects [149]. Thus, 
IL-22  may  have  a  better  therapeutic  potential  than 
IL-6  in  treating  patients  with  fatty  liver  disease  or 
acute  liver  failure  induced  by  acute  viral  hepatitis, 
ischemia/reperfusion,  liver  transplantation,  and  al-
coholic hepatitis. Alcoholic hepatitis is a severe dis-
ease with up to 40% mortality within 6 months after 
the onset of the clinical syndrome [150]. Corticoster-
oids are widely used to treat alcoholic hepatitis, but 
such treatment only improves the short-term survival 
rate [150]. This may be because treatment with corti-
costeroids inhibits inflammation, which is beneficial 
for alcoholic hepatitis, but can also suppress liver re-
generation and increase the rate of bacterial infection. 
Corticosteroids plus IL-22 treatment appear to have 
multiple beneficial effects on alcoholic hepatitis such 
as IL-22 preventing hepatocellular damage, promot-
ing hepatocyte proliferation, and inhibiting bacterial 
infection.  Clinical  trials  examining  such  therapeutic 
combinations for patients with severe alcoholic hepa-
titis should be tested in the future.  
Like many other types of cancer, hepatocellular 
carcinoma and cholangiocarcinoma also have elevat-
ed levels of STAT3 activation [4]. Blockage of STAT3 
activation  has  been  shown  to  effectively  reduce 
hepatocellular  carcinoma  and  cholangiocarcinoma 
growth  in  vitro  and  in  in  vivo  animal  models 
[135,136,151].  During  last  several  years,  extreme  ef-
forts  have  been  made  to  develop  STAT3  inhibitors. 
These inhibitors have been extensively used in pre-
clinical studies in various types of cancer, and some of 
these inhibitors have also been tested in Phase 1 clin-
ical trials [152]. We anticipate that these STAT3 inhib-
itors will have beneficial effects in treating liver cancer 
in the future. 
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